Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease.[1] It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.[2]
Doxercalciferol is the vitamin D2 analogue of alfacalcidol.[3] It undergoes 25-hydroxylation in the liver to become the active ercalcitriol, without the involvement of kidneys.[4]
References
- Sprague S M. Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient Clinical Nephrology, 2002^
- Doxercalciferol Drugs.com^
- R. A. Upton, J. C. Knutson, C. W. Bishop, L. W. LeVan. Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone Nephrology Dialysis Transplantation, 1 April 2003^